Anastrozole

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Anastrozole (ncit:C1607)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole